![](/-/media/marketing/podcast-hub/curve-soundwavesv2.png?h=127&w=450&rev=ed628250f17d432694713eb34826fe1a&hash=D756445CB26D3B6A1B5E442D7871B2D7)
Scrip Podcasts
Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J’s Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend buyout rumors validate China biotech.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Q1’s top 10 drugs; Pfizer’s R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai regains control of ADC from BMS; RSV vaccine developers hit by declining expectations; and an interview with Amgen’s Ian Thompson.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.
![](/-/media/editorial/scrip/00_regular-column-images/chinesebiotech_podcast_1200.jpg?rev=d3d2a7761a5b4b608755f8bc405705b6&w=350&hash=0937111524C56EFA47CE6E840881483D)
China Biotech Podcast: 数据出境新规解读,EHA和ADA的中国数据发布
In this Chinese-language podcast episode, "Angus" Shipo Xie, a lawyer at Han Kun Law, joins Brian Yang to discuss the implications of China's updated Data Overseas Transfer rules issued in late March. Dexter Yan explains clinical data released by Hutchmed, Jiangsu Hengrui and Innovent Bio at the recent EHA and ADA annual conferences.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the outlook for 2025 launches; Merck confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna missteps; and Sun’s North America head talks plans and strategy.
![](/-/media/editorial/scrip/2024/06/asco_2024/sc2406_asco_image3_1200.png?rev=28f716603be74b3cbf3cfc928adda29e&w=350&hash=ECEA63C2C5AA2C7BAC1C2F239F096923)
ASCO 2024 Wrap-Up Podcast
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
![](/-/media/editorial/scrip/00_regular-column-images/sc2008_fivemustknowthings_1200_final.jpg?rev=e6ab2761c1e6477ebef4a5c11f824cfe&w=350&hash=85D113D905C9FDFC44BA47966C7DE910)
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.